X hits on this document

24 views

0 shares

0 downloads

0 comments

6 / 6

Arias

Dovepress

2. Thompson W. Classification of age-related macular degeneration. In: Alfaro DV, editor. Age-related macular degeneration: a com- prehensive textbook. New York: Lippincott Williams & Wilkins, 2005. p. 44–52. 3. Hartnett ME, Weiter JJ, Garsd A, Jalkh AE. Classification of retinal pigment epithelial detachments associated with drusen. Grafes Arch Clin Exp Ophthalmol. 1992;230:11–19. 4. Poliner LS, Olk RJ, Burgess D, Gordon ME. Natural history of retinal pigment epithelial detachments in age-related macular degeneration. Ophthalmology. 1986;93:543–551. 5. Gass JD. Serous retinal pigment epithelial detachment with a notch: a sign of occult choroidal neovascularization. Retina. 1984;4: 205–220. 6. Green WR, McDonnell PJ,Yeo JH. Pathologic features of senile macular degeneration. Ophthalmology. 1985;92:615–627. 7. Bird AC, Marshall J. Retinal pigment epithelial detachments in the elderly. rans Ophthalmol Soc UK. 1986;105:674–682. 8. Bird AC. Doyne Lecture. Pathogenesis of retinal pigment epithelial detachment in the elderly; the relevance of Bruch’s membrane change. Eye. 1991;5:1–12. 9. Singerman LJ, Stockfish JH. Natural history of subfoveal pigment epi- thelial detachments associated with subfoveal or unidentifiable choroidal neovascularization complicating age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 1989;227:501–507. 10. Elman MJ, Fine SL, Murphy RP, Patz A, Auer C. The natural history of serous retinal pigment epithelium detachment in patients with age- related macular degeneration. Ophthalmology. 1986;93:224–230. 11. Pauleikhoff D, Loffert D, Spital G, et al. Pigment epithelial detach- ment in the elderly. Clinical differentiation, natural course and patho- genetic implications. Graefes Arch Clin Exp Ophthalmol. 2002;240: 533–538. 12. Teeters VW, Bird AC. The development of neovascularization of senile disciform macular degeneration. Am J Ophthalmol. 1973;76:1–18. 13. Slakter JS,Yannuzzi LA, Sorenson JA, Guyer DR, Ho AC, Orlock DA. A pilot study of indocyanine green videoangiography-guided laser photocoagulation of occult choroidal neovascularization in age-related macular degeneration. Arch Ophthalmol. 1994;112:465–472. 14. Moorfields Macular Study Group. Treatment of senile disciform macular degeneration: a single-blind randomised trial by argon laser photocoagulation. Br J Ophthalmol. 1982;66:745–753. 15. Baumal CR, Reichel E, Duker JS, Wong J, Puliafito CA. Indocyanine green hyperfluorescence associated with serous retinal pigment epithe- lial detachment in age-related macular degeneration. Ophthalmology. 1997;104:761–769. 16. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials–TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol. 1999;117:1329–1345. 17. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization – verteporfin in photodynamic therapy report 2. Am J Ophthalmol. 2001;131:541–560.

18. Pece A, Isola V, Vadala M, Calori G. Photodynamic therapy with verte- porfin for choroidal neovascularization associated with retinal pigment epithelial detachment in age-related macular degeneration. Retina. 2007;27:342–348. 19. Axer-Siegel R, Ehrlich R, Rosenblatt I, et al. Photodynamic therapy for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration. Arch Ophthalmol. 2004;122:453–459. 20. Wygnanski-Jaffe T, Desatnik H, Alhalel A, et al. ICG angiography- guided photodynamic therapy for large pigment epithelial detachments in age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2006;37:358–363. 21. Axer-Siegel R, Ehrlich R, Avisar I, et al. Combined photodynamic therapy and intravitreal triamcinolone acetonide injection for neo- vascular age-related macular degeneration with pigment epithelium detachment. Ophthalmic Surg Lasers Imaging. 2006;37:455–461. 22. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25:581–611. 23. Senger DR, Connolly DT, Van de Water L, Feder J, Dvorak HF. Purifica- tion and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res. 1990;50:1774–1778. 24. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805–2816. 25. Ng EW, Shima DT, Calias P, Cunningham ET Jr, Guyer DR,AdamisAP. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov. 2006;5:123–132. 26. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verte- porfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432–1444. 27. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovas- cular age-related macular degeneration. N Engl J Med. 2006;355: 1419–1431. 28. Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006;26:859–870. 29. Lynch SS, Cheng CM. Bevacizumab for neovascular ocular diseases. Ann Pharmacother. 2007;41:614–625. 30. Chan CK, Meyer CH, Gross JG, et al. Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration. Retina. 2007;27:541–551. 31. Gillies MC, WongTY. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2007;356:748–749. 32. Chang LK, Sarraf D. Tears of the retinal pigment epithelium: an old problem in a new era. Retina. 2007;27:523–534. 33. Kook D, Wolf A, Neubauer AS, et al. Retinal pigment epithelial tears after intravitreal injection of bevacizumab for AMD: Frequency and progress. [In German]. Ophthalmologe. 2008;105:158–164. 34. Ronan SM, Yoganathan P, Chien FY, et al. Retinal pigment epithelium tears after intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina. 2007;27:535–540.

Clinical Ophthalmology

Dovepress

Publish your work in this journal

Clinical Ophthalmology is an international, peer-reviewed journal covering all subspecialties within ophthalmology. Key topics include: Optometry; Visual science; Pharmacology and drug therapy in eye diseases; Basic Sciences; Primary and Secondary eye care; Patient Safety and Quality of Care Improvements. This journal is indexed on

PubMed Central and CAS, and is the official journal of The Society of Clinical Ophthalmology (SCO). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/ testimonials.php to read real quotes from published authors.

Submit your manuscript here: http://www.dovepress.com/clinical-ophthalmology-journal

374

submit your manuscript | www.dovepress.com Dovepress

Clinical Ophthalmology 2010:4

Document info
Document views24
Page views24
Page last viewedSun Dec 04 10:22:18 UTC 2016
Pages6
Paragraphs177
Words3833

Comments